Notice of becoming a wholly-owned subsidiary by Nippon Shokubai
Lilac Pharma Inc. (Head office: Kita-ku, Sapporo, Hokkaido; Representative Director: Motoki Susa; hereinafter referred to as ‘Lilac Pharma’) has agreed to become a wholly-owned subsidiary of Nippon Shokubai Co Ltd (Head office: Chuo-ku, Osaka; President: Kazuhiro Noda; hereinafter referred to as ‘Nippon Shokubai’) as of 9 December 2024, Ltd.
Lipid nanoparticles such as liposomes in cosmetics and pharmaceuticals are attracting increasing attention as a revolutionary material that can add value to products containing active ingredients, as they contribute to improving the stability and permeability of the active ingredients contained within.
Lilac Pharma is developing its business based on lipid nanoparticle production technology that focuses on the ‘size’ of lipid nanoparticles. Unlike conventional methods, the unique iLiNP microfluidic device invented by Hokkaido University can easily and continuously produce lipid nanoparticles of uniform size and high quality. Furthermore, the size of the nanoparticles can be adjusted over a wide range, making it a promising technology for the production of highly functional lipid nanoparticles. For more information, please see the ‘Our Technology’ page on our website.
Nippon Shokubai and Lilac Pharma started joint research in 2019 and have so far succeeded in developing several highly stable cosmetic liposomes. The acquisition of Lilac Pharma as a subsidiary will accelerate the improvement of R&D efficiency and the establishment of a stable supply system for products in both the pharmaceutical and cosmetics fields, with the aim of further expanding the business.
